Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs Becton Dickinson and Co (BDX) Price & Performance

Barclays PLCTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs Becton Dickinson and Co — how do they compare? Barclays PLC trades at $27.86 (market cap $90.80B), while Becton Dickinson and Co trades at $154.29 (market cap $42.39B). The key difference: Barclays PLC is far larger — about 2.1× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.73%). Which is the better fit depends on your goals.

BCSBDX
Market Cap
$90.80B$42.39B
Sector
FinancialsHealth
52-Week High
$28.41$185.39
52-Week Low
$18.48$135.49
Dividend Yield
1.68%2.73%
Enterprise Value
$58.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.

The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.

Becton Dickinson and Co

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX